SAN DIEGO--Triad Biotechnology recently purchased software from Pharmacopeia subsidiary Molecular Simulations (MSI). Triad will use MSI's Cerius 2 modeling software to assist its research efforts in structural genomics-based drug discovery. Triad said it plans to engineer antimicrobial drug candidates to leverage the availability of recently released microbial genomic information and address growing drug resistance observed in microbes such as Mycobacterium tuberculosis, Staphylococcus aureus, and Helicobacter pylori. Daniel Sem, Triad's vice-president for biophysics, said, "MSI's Cerius 2 modeling software will play a pivotal role in helping Triad engineer desired changes into molecules without losing their already advantageous properties."
Triad Biotechnology Buys Cerius 2 Software From Molecular Simulations
Nov 21, 1998